News & Insights

Where next for Novo Nordisk?

October 24, 2025

Time to Read: 3:47 mins

In this video, Walter Scott client investment manager Murdo MacLean considers Novo Nordisk’s recent challenges and touches on what the future could look like for the Danish pharma giant.

Key points:

Unprecedented demand for GLP-1 weight-loss drug has strained Novo Nordisk and competitor Eli Lilly’s early supply.
Rival online firms have offered cheaper generic versions of these drugs by exploiting US Food and Drug Administration (FDA) loopholes.
Both Novo and Lilly have expanded manufacturing capacity and pivoted to direct-to-consumer to control pricing and margins.
New Novo CEO brings sharper execution, clearer pipeline communication, and market-focused strategy.
Novo is planning on launching the first oral GLP-1 in early 2026.

2731800 Exp: 16 January 2026

IFMH | Equities

Healthcare: alive and well

The outlook for the healthcare sector remains positive despite its recent challenges, says Walter Scott client investment manager George Dent.

Article | Equities

Are U.S. Equity Valuations Too Rich?

With the S&P 500® hitting new highs, investors question if fundamentals or hype is fueling the rally. Despite uncertainty, the S&P 500 has delivered strong performance year to date. Its price-to-earnings (PE) ratio now sits at 22x above the nearly 17x long-term average. To some, that screams “overvalued,” but context matters.

expanding-the-investment-universe-in-global-infrastructure-tile-580x325px

Article | Equities

Beyond the grid: expanding the investment universe in global infrastructure

BNY Investments Newton’s investment strategists Brian Blongastainer and Carolina Ortega explain why they expect to see a major acceleration in global infrastructure spending over the next decade, driven by new investment opportunities fuelled by the growth in artificial intelligence (AI).